IRCT20200105046010N37招募中未知
In- Vivo Bioequivalence study of Azithromycin capsules 250 mg (Kharazmi Pharmaceuticals, Iran) with brand drug (ZITHROMAX® 250 mg Pfizer, Ireland) in Iranian healthy volunteers.
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 30 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
尚未招募
Unknown
Bioequivalence evaluation of Azithromycin Capsule 500 mg of Mahban Pharmaceutical companyIRCT20200625047913N15Hezareh Sevom Futuristic Pharmacist24
尚未招募
不适用
Bioequivalence evaluation of Azithromycin Capsule 500 mg/ Suspension 200 mg/5 ml manufactured by Dora Darou company-.IRCT20200625047913N3Hezareh Sevom Futuristic Pharmacist24
尚未招募
不适用
Bioequivalence study of Azithromycin 500 mg tabletIn the present study, no diseases will be examined and products will be administered by healthy volunteers..IRCT20210519051345N4Tabriz University of Medical Sciences24
尚未招募
Unknown
In-vivo Bioequivalence Study of Azithromycin 500 mg Capsules of The Test Drug (ZITHROSAD 500 mg Cap., Sajjad Darou, Iran)IRCT20200105046010N107Sajad darou shargh24
尚未招募
不适用
Investigating the in vivo bioequivalence of Azithromycin 250 mg capsuleIRCT20210519051345N13Tabriz University of Medical Sciences24